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The bacterial CRISPR-Cas9 system has emerged
as an effective tool for sequence-specific gene
knockout through non-homologous end joining
(NHEJ), but it remains inefficient for precise editing
of genome sequences. Here we develop a reporter-
based screening approach for high-throughput iden-
tification of chemical compounds that can modulate
precise genome editing through homology-directed
repair (HDR). Using our screening method, we
have identified small molecules that can enhance
CRISPR-mediated HDR efficiency, 3-fold for large
fragment insertions and 9-fold for point mutations.
Interestingly, we have also observed that a small
molecule that inhibits HDR can enhance frame shift
insertion and deletion (indel) mutations mediated
by NHEJ. The identified small molecules function
robustly in diverse cell types with minimal toxicity.
The use of small molecules provides a simple and
effective strategy to enhance precise genome engi-
neering applications and facilitates the study of DNA
repair mechanisms in mammalian cells.
The bacterial adaptive immune system CRISPR (clustered
regularly interspaced palindromic repeats)-Cas (CRISPR asso-
ciated protein) has been used for the sequence-specific editing
of mammalian genomes (Barrangou et al., 2007; Cong et al.,
2013; Gonza´lez et al., 2014; Mali et al., 2013; Smith et al.,
2014; Wang et al., 2013; Yang et al., 2013a). The CRISPR
system derived from Streptococcus pyogenes uses a Cas9
nuclease protein that complexes with a single guide RNA
(sgRNA) containing a 20-nucleotide (nt) sequence for intro-
ducing site-specific double-stranded breaks (Hsu et al., 2013;
Jinek et al., 2012). Targeting of the Cas9-sgRNA complex to
DNA is specified by basepairing between the sgRNA and
DNA as well as the presence of an adjacent NGG PAM (proto-
spacer adjacent motif) sequence (Marraffini and Sontheimer,142 Cell Stem Cell 16, 142–147, February 5, 2015 ª2015 Elsevier Inc2010). The double-stranded break occurs 3 bp upstream of
the PAM site, allowing targeted sequence modifications via
alternative DNA repair pathways: either non-homologous end
joining (NHEJ) that introduces frame shift insertion and deletion
(indel) mutations leading to loss-of-function alleles (Geurts
et al., 2009; Lieber and Wilson, 2010; Sung et al., 2013; Tesson
et al., 2011; Wang et al., 2014) or homology-directed repair
(HDR) for precise insertion of point mutations or a fragment
of desired sequence at the targeted locus (Mazo´n et al.,
2010; Wang et al., 2014; Yin et al., 2014).
To date, CRISPR-mediated gene knockout through NHEJ-
induced indel mutations has worked efficiently. For example,
the efficiency for knocking out a protein-coding gene has been
reported to be 20%–60% in mouse embryonic stem cells
(ESCs) and zygotes (Wang et al., 2013; Yang et al., 2013a). How-
ever, precise introduction of a point mutation or a sequence
fragment directed by a homologous template has remained inef-
ficient (Mali et al., 2013; Wang et al., 2013; Yang et al., 2013a). A
long and tedious screening process via cell sorting or selection,
expansion, and sequencing is often required to identify correctly
edited cells. Improving the efficiency of precise CRISPR gene
editing remains a major challenge.
It has been shown that small molecule compounds can effec-
tively activate or block certain DNA repair pathways (Hollick
et al., 2003; Rahman et al., 2013; Srivastava et al., 2012). How-
ever, it remains unclear whether small molecules could be
used to modulate CRISPR-induced genome editing and DNA
repair via the HDRpathway. Herewe sought to identify new small
molecules that can enhance HDR for more efficient and precise
gene insertion or point mutations.
To quantitatively characterize CRISPR-mediated HDR effi-
ciency, we established a fluorescence reporter system in E14
mouse ESCs. We used ESCs in the screening assay because
ESCs exhibit overall better HDR efficiencies compared to so-
matic cells (Kass et al., 2013), thus providing an easier system
for measuring the gene insertion frequency. To create the
reporter system, we co-transfected ESCs via electroporation
with three plasmids: a Cas9-expressing vector, a sgRNA-ex-
pressing vector targeting the stop codon of Nanog (sgNanog),
and a circular template plasmid containing a promoterless.
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Figure 1. Establishment of a High-
Throughput Chemical Screening Platform
for Modulating CRISPR-Mediated HDR
Efficiency
(A) A fluorescence reporter system in E14 mouse
ESCs to characterize the HDR efficiency. An
sfGFP-encoding template is inserted at the Nanog
locus. The PAM is labeled in green, the stop codon
is shown in red, and the sgRNA target site is
shaded in gray. The cutting site (scissors) is 3 bp
downstream of 50-CCA-30 in this case. The binding
sites of two sets of primers are shown by arrows.
Primer set #1 binds to the sequences outside of
the homology arms, and primer set #2 contains a
forward primer binding to the sfGFP sequence
and a reverse primer binding outside of the 30 ho-
mology arm.
(B) Fluorescence histograms of mouse ESCs
transfected with different plasmid combinations
using flow cytometry analysis. (C) Sequencing re-
sults of the Nanog locus in GFP-positive cells.
(D) A scheme of the chemical screening platform
and a waterfall plot of 3,918 small molecules
screened for their activity of CRISPR-mediated
gene insertion. Highlighted dots are validated
compounds that showed increased or decreased
insertion efficiency. The dotted line showed the
mean value of all screened compounds.
(E) Validation of two enhancing and two repressing
compounds using flow cytometry analysis.
(F) Efficiency of sfGFP insertion into the Nanog lo-
cus. Gel pictures show sfGFP tagging using two
sets of primers as shown in Figure 1A. The PCR
products of primer set #1 were purified, cloned to a
modified pUC19backbone vector, and sequenced.
(G) Dose-dependent effects of four compounds
for modulating CRISPR gene editing. All data are
normalized to the knockin efficiency of DMSO-
treated control cells (dotted lines). Error bars
represent the SD of three biological replicates.superfolder GFP (sfGFP) with an N-terminal in-frame 2A pep-
tide (p2A) and two copies of nuclear localization sequence
(NLS) (Figure 1A). The template also contains two sfGFP-flank-
ing homology arms to Nanog, a 1.8 kilobase (kb) left arm,
and a 2.4 kb right arm. CRISPR-mediated insertion of the
p2A-NLSx2-sfGFP sequence into the endogenous Nanog locus
was measured by gain of green fluorescence using flow cytom-
etry 3 days after electroporation. Our results showed that only
co-delivery of all three plasmids yielded GFP-positive ESCs
(17% of cells showing strong fluorescence), but the controls
lacking any of the three plasmids generated almost no GFP-
positive cells (Figure 1B). To confirm correct insertion of theCell Stem Cell 16, 142–147template into the Nanog locus in GFP-
positive cells, we sorted GFP-positive
cells, PCR amplified, and sequenced
to verify the target locus. We observed
correct sfGFP integration in GFP-positive
cells (Figure 1C). Furthermore, we de-
tected no fluorescence signal when using
a template without homology arms (Fig-
ure S1A). Together, the experiments sug-gested a correlation between gain of fluorescence and HDR-
mediated precise gene insertion.
To investigate a broad range of small molecules that could
act as enhancers or inhibitors of CRISPR-mediated HDR, we
developed a high-throughput chemical screening assay based
on the reporter system (Figures 1D and S1B). In this assay,
mouse ESCs were co-transfected with Cas9, sgNanog, and
the template and seeded at a density of 2,000 cells per well
into Matrigel-coated 384-well plates containing the LIF-2i me-
dium supplemented with individual compounds from our known
drug collections (Supplemental Information). After 3 days of cul-
ture, cells were fixed, stained with DAPI, and imaged using an, February 5, 2015 ª2015 Elsevier Inc. 143
automated high-content IN Cell imaging system for the analysis
of the numbers of DAPI-positive and GFP/DAPI double-positive
nuclei in each well.
From a collection of roughly 4,000 small molecules with known
biological activity, we identified and confirmed using flow cytom-
etry that two small molecules, L755507 and Brefeldin A, could
improve the HDR efficiency (Figures 1D and 1E). L755507, a
b3-adrenergic receptor agonist (Parmee et al., 1998), increased
the efficiency of GFP insertion by 3-fold compared to DMSO-
treated control cells, whichwas further verified byPCRamplifica-
tion and sequencing of the target locus (Figures 1E and 1F). Bre-
feldin A, an inhibitor of intracellular protein transport from the ER
to the Golgi apparatus (Ktistakis et al., 1992), also exhibited
enhanced insertion efficiency by 2-fold (Figures 1E and 1F).
Interestingly, we also identified that two thymidine analogs,
azidothymidine (AZT) and Trifluridine (TFT), could decrease the
HDR efficiency (Figures 1D and 1E). AZT, previously used as
an anti-HIV drug that inhibits the reverse transcriptase activity
(Mitsuya et al., 1985), and TFT, which was identified as an anti-
herpes virus drug that functioned by blocking viral DNA replica-
tion (Little et al., 1968), decreased the HDR efficiency by 3-fold
as assayed using flow cytometry (Figure 1E), or by more than
10-fold as detected by sequencing (Figure 1F).
We further examined the dosage effects, treatment duration,
and cytotoxicity of the identified small molecules. We found
that HDR enhancers L755507 and Brefeldin A achieved their
maximal effects at 5 mM and 0.1 mM, respectively (Figure 1G).
The HDR inhibitors AZT and TFT exhibited maximal effects at
5 mM. In addition, we also examined compound treatment win-
dows of 0–24 hr, 24–48 hr, 48–72 hr, or 0–72 hr postelectropora-
tion. All compounds showed optimal activity within the first 24 hr,
suggesting that the genome knockin events occurred mostly
during the first 24 hr in our system (Figure S1C). Notably, at
their optimized concentrations, the compounds exhibited no or
very mild toxicity as assayed by both cell counts and MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) cell proliferation assay (Figures
S1D and S1E).
To test how generally these compounds can be used for
modulating HDR for different genomic loci and in different cell
types, we used another template to insert a t2A-Venus cassette
in-frame into the locus of Alpha Smooth Muscle Actin (ACTA2)
(Figure 2A), a gene expressed in awide variety of cancer cell lines
and normal cells (Ueyama et al., 1990). The template plasmid
contains a left homology arm of 780 bp and a right homology
arm of 695 bp that flank the t2A-Venus cassette. We first co-
transfected the template plasmid with a single construct ex-
pressing both Cas9 and sgACTA2 into HeLa cells. Sequencing
results of Venus-positive HeLa cells confirmed that Venus
expression represented the correct insertion of Venus into the
ACTA2 locus (Figure 2B). We then tested several other types of
human cells. Our flow cytometry results showed that the knockin
efficiency was dependent on the cell type, ranging from 0.8%
to 3.5%. Treating different types of cells with L755507 showed
consistently improved HDR efficiency, with the largest in-
crease of more than 2-fold in human umbilical vein endothelial
cells (HUVECs). The fact that L755507 consistently increased
the HDR efficiency in diverse cells including cancer cell lines
(K562 and HeLa), suspension cells (K562), primary neonatal144 Cell Stem Cell 16, 142–147, February 5, 2015 ª2015 Elsevier Inccells (HUVEC and fibroblast CRL-2097), and human ESC-
derived cells (neural stem cells) (Li et al., 2011) suggested that
the mechanism by which L755507 enhances CRISPR-mediated
HDR was common in both transformed and primary cells.
Precise editing of SNPs through single-stranded oligodeoxy-
nucleotide (ssODN) templates is an important application of
genome editing in disease modeling and gene therapy. We
next sought to test whether the identified small molecules
could enhance SNP editing through HDR using a short ssODN.
The method for introducing mutations into human induced
pluripotent stem cells (iPSCs) using CRISPR-Cas9 and ssODN
has been established (Ding et al., 2013b; Yang et al., 2013b).
Following a similar method, we synthesized a 200-nt ssODN
template to introduce an A4V mutation into the human SOD1
locus (Figure 2D); this is one of the common mutations that
causes Amyotrophic Lateral Sclerosis (ALS) in the U.S. popula-
tion (Rosen et al., 1994). We designed an sgRNA (sgSOD1) in
such a way that introduction of the A4V mutation also disrupted
the NGG PAM sequence, thus preventing further targeting by
sgSOD1 to the A4V alleles. We co-transfected two vectors that
encoded Cas9 and sgSOD1 with or without the ssODN template
into human iPSCs (Ding et al., 2013a, 2013b; Zhu et al., 2010).
The cells were then treated with DMSO or L755507 followed
by genomic DNA extraction, PCR cloning, and sequencing of
randomly picked E. coli transformants. The sequencing results
showed that compared to theDMSOcontrol, L755507 enhanced
the frequency of the A4V allele mutant by almost 9-fold (Figures
2E and 2F). Our results also showed decreased indel allele mu-
tation frequency with the addition of L755507. These results
demonstrated that our small molecules could dramatically
enhance SNP editing using a short ssODN template.
We next sought to test if the small molecules repressing HDR
also affect NHEJ. We reasoned that if a small molecule directly
inhibits the DNA cutting activity of Cas9, it should also inhibit
CRISPR-mediated gene deletion without a template. To test
this, we generated a clonal mouse ESC line carrying a monoal-
lelic sfGFP insertion at the Nanog locus (Figures S2A and S2B).
We designed three sgRNAs (sgGFP-1, 2, and 3) that targeted
within the sfGFP coding sequence on the same plasmid that en-
coded Cas9 (Figure 2G). Electroporation of any sgRNA resulted
in a population of cells that showed complete loss of GFP
expression after 3 days, while ESCs transfected with an sgRNA
(sgGAL4) with no targetable sites showed no loss of the
GFP signal (Figure 2G). Addition of L755507 immediately after
electroporation showed inhibitory effects on GFP knockout. Un-
expectedly, the knockin inhibitor, AZT, greatly increased GFP
knockout efficiency for all three sgRNAs tested. For example,
AZT increased the knockout efficiency by more than 1.8-fold in
the case of sgGFP-1 (Figure 2B). This was also consistent with
the deep sequencing results for indel detection (Table S1).
Together, these results suggested that AZT acted on the NHEJ
pathway instead of interacting with the Cas9-sgRNA complex,
and they also suggested a possible trade-off between the HDR
and NHEJ pathways.
Staining of pluripotency markers Oct4, Sox2, and Nanog
showed that the compounds did not affect pluripotency (Figures
S2C and S2D). Furthermore, neither electroporation (Figure S2E)
nor compound addition (Figure S2F) affected Nanog expression.
To rule out the possibility that the AZT does not cause more.
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Figure 2. Different Identified Small Molecules Could Enhance HDR or NHEJ-Mediated CRISPR Genome Editing
(A) A scheme of insertion strategy at the human ACTA2 locus (top). The PAM is labeled in green, and the sgRNA target site is shaded in gray.
(B) Sequencing results of the ACTA2 locus in Venus-positive HeLa cells.
(C) Efficiency of Venus insertion measured by flow cytometry analysis. The error bars indicate the SD of three samples, and the p values are calculated using a
two-tailed Student’s t test. *p < 0.05; **p < 0.01.
(D) The strategy for introducing the A4V point mutation at the human SOD1 locus in human iPSCs. The PAM is labeled in green, and the sgRNA target site is
shaded in gray. The point mutation is labeled in red.
(E) Sequencing results of the SOD1 locus.
(F) Comparison of A4V allele mutant frequency and indel allele frequency in human iPSCs as assayed by PCR cloning and bacterial colony sequencing with no
template, DMSO, or L755507.
(G) Test of knockout efficiency using a clonal mouse ESC line carrying a monoallelic sfGFP insertion at theNanog locus in the presence of L755705 and AZT. The
dot plots of cells transfected with a non-cognate sgRNA (sgGAL4) are shown on the top. The panel shows cells transfected with three different sgRNAs (with their
target sites shown in the scheme) in the presence of DMSO (left), L755507 (middle), and AZT (right).
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errors in replication that in turn lead to inactivation of GFP, we
passaged Nanog-sfGFP ESC lines for 10 passages under AZT
treatment without the CRISPR components and observed no
loss of GFP signals (Figure S2G). These results also showed
that the compounds identified in the screening system could
modulate CRISPR-mediated gene knockout.
In summary, we developed a high-throughput chemical
screening platform for CRISPR genome editing and provided
proof-of-principle demonstration that small molecules could be
used to modulate the efficiency of CRISPR genome editing.
We report several small molecules that could enhance or repress
HDR-mediated precise gene editing. The identified compounds
likely interact with the NHEJ or HDR DNA repair pathways, thus
providing a set of useful tools for themechanistic interrogation of
these pathways. The identified chemicals exhibit minimal toxicity
and work in diverse cell types, which can be used to enhance
both large template-mediated gene insertion and ssODN-medi-
ated SNP editing. We also report small molecules that can
enhance gene knockout without a template. The observation
that reducing HDR could increase NHEJ may suggest a trade-
off between the two DNA repair pathways after DNA cutting by
the Cas9 nuclease. Identification of diverse classes of small mol-
ecules provides an approach that facilitates precise CRISPR
genome editing for both biomedical research and clinical
applications.
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